Version of Record online: 2 JUL 2004
Copyright © 2004 American Cancer Society
Volume 101, Issue 5, page 1101, 1 September 2004
How to Cite
Weiser, M. A. (2004), Author reply. Cancer, 101: 1101. doi: 10.1002/cncr.20462
- Issue online: 18 AUG 2004
- Version of Record online: 2 JUL 2004
Büyükçelik et al. raise a valid question regarding the relation between hyperglycemia and dose reduction during chemotherapy with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) for the treatment of acute lymphocytic leukemia. We reviewed the data and found that 62% of patients with hyperglycemia (defined as a random serum glucose level of ≥ 200 mg/dL on 2 or more determinations during the first 30 days of treatment) had a dose reduction at some time during treatment, compared with 60% of patients without hyperglycemia. Therefore, there does not appear to be an association between hyperglycemia and the risk for reduction in dose intensity in this patient population.
- 1Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphoblastic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer. 2004; 100: 1179–1185., , , et al.